The how's and what's of vaccine reactogenicity.

Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. · 2019

Read The how's and what's of vaccine reactogenicity. by Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6760227.txt.

Introduction

Hervé and co-authors explain vaccine reactogenicity, the short-term reactions that follow a shot. These include sore, red, or swollen arms, plus fever, muscle ache, and headache. Such symptoms are the visible side of the inflammation a vaccine is meant to provoke. Bad experiences can breed needle fear and lasting refusal, though.

The review covers what drives these reactions. Host traits, how the shot is given, and what the vaccine contains all play roles. Early immune cells reach the injection site within hours in animal studies. The authors aim to help vaccine teams set honest expectations. Calmer, better-informed vaccination visits should protect public confidence in vaccines.

Catalog record

CREATORHervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6760227

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The how’s and what’s of vaccine reactogenicity By Caroline Hervé, Béatrice Laupèze, Giuseppe Del Giudice, Arnaud M. Didierlaurent, Fernanda Tavares Da Silva Published in: NPJ Vaccines DOI: 10.1038/s41541-019-0132-6 ABSTRACT Reactogenicity represents the physical manifestation of the inflammatory response to vaccination, and can include injection-site pain, redness, swelling or induration at the injection site, as well as systemic symptoms, such as fever, myalgia, or headache. The experience of symptoms following vaccination can lead to needle fear, long-term negative attitudes and non-compliant behaviours, which undermine the public health impact of vaccination. This review presents current knowledge on the potential causes of reactogenicity, and how host characteristics, vaccine administration and composition factors can influence the development and perception of reactogenicity. The intent is to provide an overview of reactogenicity after vaccination to help the vaccine community, including healthcare professionals, in maintaining confidence in vaccines by promoting vaccination, setting expectations for vaccinees about what might occur after vaccination and reducing anxiety by managing the vaccination setting. REACTOGENICITY AFTER VACCINATION Reactogenicity refers to a subset of reactions that occur soon after vaccination, and are a physical manifestation of the inflammatory response to vaccination. In clinical trials, information on expected signs and symptoms after vaccination is actively sought (or ‘solicited’). These symptoms may include pain, redness, swelling or induration for injected vaccines, and systemic symptoms, such as fever, myalgia, headache, or rash. The broader term ‘safety’ profile refers to all adverse events (AEs) that could potentially be caused/triggered or worsened at any time after vaccination, and includes AEs, such as anaphylactic reactions, diseases diagnosed after vaccination and autoimmune events. Thousands of vaccines are administered every day and the vast majority induce few symptoms in the recipient. Those symptoms that do occur early after vaccination are usually mild and self-limiting and rarely have serious medical consequences. Nevertheless, understanding the range of symptoms that vaccination might cause is important for the person receiving the vaccine, for caregivers/decision-makers deciding to accept vaccination for others, and for the healthcare professionals who recommends and administers vaccines. Reactogenicity can contribute to a person’s willingness to be vaccinated. If a vaccine is perceived as too reactogenic, the subject may refuse further doses, or the healthcare professional may elect not to recommend it, leading to incomplete protection of the individual and low vaccine coverage in the population. Maintaining high vaccine coverage is critical to the success of vaccination programs. The majority of vaccines available today are administered parenterally via injection. Knowledge about the symptoms that can occur after vaccination can be used by healthcare professionals to prepare patients on what to expect after vaccination, potentially leading to improved compliance and higher acceptance of subsequent doses. This review presents current knowledge on what potentially causes reactogenicity, and how host characteristics, vaccine composition and vaccine administration techniques influence the development and perception of reactogenicity. We summarise current recommendations for pain mitigation at the time of vaccination, including the benefits and risks of using antipyretics to prevent symptoms. EVALUATION OF VACCINE REACTOGENICITY AND SAFETY The current attitude regarding the benefits versus the risks of vaccination puts a large emphasis on safety, because vaccines are usually given to healthy populations who may receive no immediate health benefit, particularly when the incidence of the target infectious disease is low. Vaccine reactogenicity and safety is assessed at all points of the vaccine development process, from preclinical toxicology studies using cell cultures and animal models, to rigorous assessment in clinical studies and post-licensure pharmacovigilance.1 Following licensure, safety remains of prime concern; ongoing surveillance evaluates vaccine safety in large populations under real-world settings. Fundamental to this process is the contribution of the Brighton Collaboration, a network whose aim is to establish clear case definitions for individual events following vaccination, and to thereby ensure high-quality data collection and reporting consistency.2,3 Pre-clinical evaluation investigating injection-site reactions and the toxicological profile of vaccines is a prerequisite to the initiation of clinical trials in which safety and efficacy are established. However, while preclinical studies are critical to identify signals that would prevent their use in humans, evaluation in the early phase of clinical development is needed to confirm the safety profile of the vaccine in humans. Systematic collection of safety data in clinical trials follows guidelines set out by competent regulatory agencies, such as the European Medicines Agency, the US Food and Drug Administration and World Health Organization (WHO). Authorities also advise on the size of the safety database needed to provide reasonable assurance that the reactogenicity and safety profile of the vaccine is acceptable. In clinical trials, reactogenicity is measured by collecting sets of injection site and systemic signs and symptoms that are solicited from study participants over a specified time after vaccination. The types of symptoms collected and the period for which they are collected depend on the vaccine being investigated and the objectives of individual studies. Reactions that are solicited (in which participants are actively questioned about the occurrence of each symptom) are usually reported at higher frequencies than the same symptoms when participants are asked to report them spontaneously (unsolicited symptoms). While some signs can be objectively measured (body temperature, redness, swelling, heart rate), other symptoms are non-specific and subjective, and are perceived differently depending on a range of factors occurring at the time. These factors can include mood, presence of other medical conditions or symptoms, climate, individual perceptions of pain, etc. Effects of symptoms on an individual’s physical functioning and quality of life, reduced work efficiency or use of healthcare resources or medications are also difficult to assess quantitatively. Furthermore, many illnesses and general conditions cause the same signs and symptoms (for example, fever, headache, fatigue), making it challenging to determine what is, and what is not caused by vaccination. A double-blind study conducted in 581 twin pairs in Finland illustrated this problem.4 One twin received measles-mumps-rubella vaccine (MMR) followed by placebo injection 3 weeks later, while the second twin received the injections in the reverse order. The study showed that during the time of peak incidence of fever, 88% of low-grade fever, 24% of moderate fever and 7% of high fever episodes were not caused by the vaccine. These observations highlight the importance of an appropriate control group (such as placebo) in clinical trials in order to be able to untangle which proportion of signs or symptoms might be caused by vaccination. After authorization, vaccine safety is monitored through pharmacovigilance activities conducted by the manufacturer, regulatory authorities and independent researchers, such as review of spontaneous reports of AEs received from healthcare professionals, lay persons and regulatory agencies world-wide. Investigation of specific AEs of interest may continue in targeted safety studies conducted post-licensure. When needed, the prescribing information is updated to reflect the latest safety data. WHAT CAUSES REACTOGENICITY? Vaccines contain antigens that induce an immune response capable of providing specific protection from disease. Individual vaccine antigens induce innate immune responses that may differ qualitatively or quantitatively according to the vaccine composition, but that induce a good adaptive immune response. After entering the body, vaccine antigens are recognised as potential pathogens by conserved pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), pattern-recognition receptors (PRRs) including Toll-like receptors (TLR)5 that are found on local or peripheral circulating immune cells (e.g. monocytes

Read the complete text